REVIEW article
Front. Nutr.
Sec. Clinical Nutrition
Long-term/home parenteral nutrition: expert consensus statements regarding intravenous lipid emulsions
Provisionally accepted
- 1Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, United States
- 2Department of Surgery, Oregon Health & Science University, Portland, United States
- 3University of Southampton Faculty of Medicine, Southampton, United Kingdom
- 4Surgical Oncology Clinic, The Maria Sklodowska-Curie National Cancer Institute, Krakow, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Home parenteral nutrition (HPN) is the primary life-saving therapy for patients with chronic intestinal failure (CIF). Patients requiring palliative nutrition, such as those with advanced cancer, may also benefit from HPN. Lipids are an integral part of parenteral nutrition (PN), but the use of intravenous lipid emulsions (ILEs) in PN continues to raise numerous questions for clinicians despite improved understanding and knowledge. The Lipids in PN Summit involved a panel of international experts with extensive research and clinical experience in use of PN. They assessed the current state of knowledge and developed expert consensus statements regarding the use of ILEs in patients requiring PN. The statements are also provided to help bridge the gaps between evidence and clinical practice, hence complementing formal societal guideline recommendations for the use of PN. This review briefly summarizes the rationale for considering ILE choice as a central component of any strategy for HPN patients, and discusses aspects of special interest within the context of HPN and long-term PN use in general such as essential fatty acid (EFA) delivery, the prevention of IF-associated liver disease (IFALD), and clinical evidence within HPN populations. In particular, potential clinical advantages of modern composite ILEs containing fish oil are reviewed, with biological effects of omega-3 polyunsaturated fatty acids (PUFAs) imparting additional clinical benefits. A future perspective section shares some proposals to address the difficulties of data generation within HPN, and suggested approaches to take as part of current clinical practice in the absence of definitive data. For now, the existing body of evidence should provide the basis for clinical care, and where evidence is lacking expert recommendations must suffice. The consensus statements from the Lipid Summit aim to summarize aspects mostly relevant for everyday clinical care; those relevant to the HPN setting are presented in this review.
Keywords: consensus, fish oil, guidelines, Home parenteral nutrition, intestinal failure, Lipids, Omega-3 fatty Acids, palliative nutrition
Received: 03 Oct 2025; Accepted: 11 Nov 2025.
Copyright: © 2025 Mundi, Martindale, Calder and Klek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Manpreet S Mundi, richard.clark@medicalwriting.plus.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.